Literature DB >> 7230725

[Results of treatment with ABVD in C-MOPP-resistant Hodgkin's disease (author's transl)].

W Gassmann, L Perenyi, H Pralle, M Graubner, N Schmitz, H Löffler.   

Abstract

22 Patients were treated with ABVD, 19 (18 stage IV B 1 stage III B) could be evaluated. No patient with impaired but 7 of 13 patients with intact bone-marrow function achieved a complete remission. A complete remission was also achieved by all 4 patients with a treatment- and disease-free interval but only by 3 of 15 without a free interval. Pretreatment, histology, duration of disease, and age showed no clear prognostic significance with respect to induction of remission. Toxicity was severe especially in patients over 50 years of age. 2 patients discontinued therapy because of gastro-intestinal toxicity. 2 of 8 died of treatment-related causes (1 leukemia, 1 sudden cardiac death). In 3 patients with high-dose mediastinal irradiation a pneumonitis secondary to bleomycin contributed significantly to death. Our results suggest that ABVD is an effective salvage-regimen for some subgroups of MOPP-failures.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7230725     DOI: 10.1007/bf01478205

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  35 in total

1.  The changing face of Hodgkin's disease.

Authors:  A C Aisenberg; R M Linggood; R A Lew
Journal:  Am J Med       Date:  1979-12       Impact factor: 4.965

2.  Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease.

Authors:  J G Krikorian; J S Burke; S A Rosenberg; H S Kaplan
Journal:  N Engl J Med       Date:  1979-03-01       Impact factor: 91.245

3.  5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma.

Authors:  E Frei; J K Luce; R W Talley; V K Vaitkevicius; H E Wilson
Journal:  Cancer Chemother Rep       Date:  1972-10

4.  A clinical review of bleomycin--a new antineoplastic agent.

Authors:  R H Blum; S K Carter; K Agre
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

5.  MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients.

Authors:  M R Moore; S E Jones; J M Bull; L A William; S A Rosenberg
Journal:  Cancer       Date:  1973-07       Impact factor: 6.860

6.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

7.  Second malignancies complicating Hodgkin's disease in remission.

Authors:  G P Canellos; J C Arseneau; V T DeVita; J Whang-Peng; R E Johnson
Journal:  Lancet       Date:  1975-04-26       Impact factor: 79.321

8.  New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease.

Authors:  J J Lokich; E Frei; N Jaffe; J Tullis
Journal:  Cancer       Date:  1976-08       Impact factor: 6.860

9.  Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure.

Authors:  K J Porzig; C S Portlock; A Robertson; S A Rosenberg
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

10.  Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute.

Authors:  V T DeVita; R M Simon; S M Hubbard; R C Young; C W Berard; J H Moxley; E Frei; P P Carbone; G P Canellos
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391

View more
  2 in total

1.  [Treatment results of Hodgkin's disease, stages I and II (author's transl)].

Authors:  W Gassmann; H Pralle; H Löffler; M Gluth-Stender
Journal:  Klin Wochenschr       Date:  1981-05-15

2.  Prognostic factors in COPP-treated patients with Hodgkin's disease.

Authors:  W Gassmann; L Perenyi; N Schmitz; W Kayser; H Pralle; H Löffler
Journal:  Blut       Date:  1982-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.